BRPI0812795C1 - domínio variável único de imunoglobulina, antagonista tipo 1 do receptor tnfalfa, uso de um domínio ou antagonista de tnfr1, ácido nucleico recombinante, vetor, célula hospedeira, e, composição farmacêutica - Google Patents

domínio variável único de imunoglobulina, antagonista tipo 1 do receptor tnfalfa, uso de um domínio ou antagonista de tnfr1, ácido nucleico recombinante, vetor, célula hospedeira, e, composição farmacêutica

Info

Publication number
BRPI0812795C1
BRPI0812795C1 BRPI0812795A BRPI0812795A BRPI0812795C1 BR PI0812795 C1 BRPI0812795 C1 BR PI0812795C1 BR PI0812795 A BRPI0812795 A BR PI0812795A BR PI0812795 A BRPI0812795 A BR PI0812795A BR PI0812795 C1 BRPI0812795 C1 BR PI0812795C1
Authority
BR
Brazil
Prior art keywords
antagonist
tnfr1
tnfalfa
vector
nucleic acid
Prior art date
Application number
BRPI0812795A
Other languages
English (en)
Portuguese (pt)
Inventor
Enever Carolyn
Tomlinson Ian
Jespers Laurent
Pupecka Malgorzata
Original Assignee
Domantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0724331.4A external-priority patent/GB0724331D0/en
Application filed by Domantis Ltd filed Critical Domantis Ltd
Publication of BRPI0812795A2 publication Critical patent/BRPI0812795A2/pt
Publication of BRPI0812795B1 publication Critical patent/BRPI0812795B1/pt
Publication of BRPI0812795B8 publication Critical patent/BRPI0812795B8/pt
Publication of BRPI0812795C1 publication Critical patent/BRPI0812795C1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
BRPI0812795A 2007-06-06 2008-06-04 domínio variável único de imunoglobulina, antagonista tipo 1 do receptor tnfalfa, uso de um domínio ou antagonista de tnfr1, ácido nucleico recombinante, vetor, célula hospedeira, e, composição farmacêutica BRPI0812795C1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93363207P 2007-06-06 2007-06-06
GBGB0724331.4A GB0724331D0 (en) 2007-12-13 2007-12-13 Compositions for pulmonary delivery
PCT/GB2008/050405 WO2008149148A2 (en) 2007-06-06 2008-06-04 Polypeptides, antibody variable domains and antagonists

Publications (4)

Publication Number Publication Date
BRPI0812795A2 BRPI0812795A2 (pt) 2014-12-02
BRPI0812795B1 BRPI0812795B1 (pt) 2019-12-03
BRPI0812795B8 BRPI0812795B8 (pt) 2020-01-28
BRPI0812795C1 true BRPI0812795C1 (pt) 2021-05-25

Family

ID=39791116

Family Applications (3)

Application Number Title Priority Date Filing Date
BRPI0812795A BRPI0812795C1 (pt) 2007-06-06 2008-06-04 domínio variável único de imunoglobulina, antagonista tipo 1 do receptor tnfalfa, uso de um domínio ou antagonista de tnfr1, ácido nucleico recombinante, vetor, célula hospedeira, e, composição farmacêutica
BRPI0813899A BRPI0813899A2 (pt) 2007-06-06 2008-06-04 domínio variável simples de imunoglobulina anti-vegf, antagonista anti-vegf, domínio variável simples de imunoglobulina resistente a protease, uso do antagonista vegf ou domínio variável, método para a dispensação oral ou dispensação de um medicamento ao trato de gi de um paciente ou ao pulmão ou tecido pulmonar ou olho de um paciente, dispositivo de dispensação pumonar, formulação oral, ligando específico duplo, ácido nucleico isolado ou recombinante, vetor célula hospedeira, método para produzir polipeptídeo, composição farmacêutica, polipeptídeo, e, proteína de fusão
BRPI0812268A BRPI0812268A2 (pt) 2007-06-06 2008-06-04 domínio variável simples de imunoglobulina tipo 1 de receptor anti-interleucina-1, antagonista tipo 1 do receptor anti-interleucina-1, uso do mesmo, método para a dispensação oral ou dispensação de um medicamento ao trato gi de um paciente ou ao pulmão ou tecido pulmonar de um paciente, dispositivo de dispensação pulmonar, formulação oral, ligando específico duplo, ácido nucleico isolado ou recombinante, vetor, célula hospedeira, método para produzir polipeptídeo, composição farmacêutica, polipeptídeo, proteína de fusão, e, ácido nucleico isolado ou recombinante.

Family Applications After (2)

Application Number Title Priority Date Filing Date
BRPI0813899A BRPI0813899A2 (pt) 2007-06-06 2008-06-04 domínio variável simples de imunoglobulina anti-vegf, antagonista anti-vegf, domínio variável simples de imunoglobulina resistente a protease, uso do antagonista vegf ou domínio variável, método para a dispensação oral ou dispensação de um medicamento ao trato de gi de um paciente ou ao pulmão ou tecido pulmonar ou olho de um paciente, dispositivo de dispensação pumonar, formulação oral, ligando específico duplo, ácido nucleico isolado ou recombinante, vetor célula hospedeira, método para produzir polipeptídeo, composição farmacêutica, polipeptídeo, e, proteína de fusão
BRPI0812268A BRPI0812268A2 (pt) 2007-06-06 2008-06-04 domínio variável simples de imunoglobulina tipo 1 de receptor anti-interleucina-1, antagonista tipo 1 do receptor anti-interleucina-1, uso do mesmo, método para a dispensação oral ou dispensação de um medicamento ao trato gi de um paciente ou ao pulmão ou tecido pulmonar de um paciente, dispositivo de dispensação pulmonar, formulação oral, ligando específico duplo, ácido nucleico isolado ou recombinante, vetor, célula hospedeira, método para produzir polipeptídeo, composição farmacêutica, polipeptídeo, proteína de fusão, e, ácido nucleico isolado ou recombinante.

Country Status (31)

Country Link
US (5) US8398979B2 (enExample)
EP (5) EP2162468A2 (enExample)
JP (3) JP5444215B2 (enExample)
KR (4) KR20100018040A (enExample)
CN (4) CN101802004A (enExample)
AR (3) AR066848A1 (enExample)
AU (4) AU2008259590A1 (enExample)
BR (3) BRPI0812795C1 (enExample)
CA (6) CA2688433A1 (enExample)
CL (3) CL2008001676A1 (enExample)
CO (2) CO6251322A2 (enExample)
CR (2) CR11195A (enExample)
CY (1) CY1116762T1 (enExample)
DK (1) DK2162467T3 (enExample)
DO (1) DOP2009000268A (enExample)
EA (5) EA200901494A1 (enExample)
ES (1) ES2546943T3 (enExample)
HR (1) HRP20151024T1 (enExample)
HU (1) HUE025899T2 (enExample)
IL (2) IL201398A0 (enExample)
MA (2) MA31403B1 (enExample)
MX (4) MX2009013137A (enExample)
NZ (1) NZ581372A (enExample)
PE (3) PE20090322A1 (enExample)
PL (1) PL2162467T3 (enExample)
PT (1) PT2162467E (enExample)
SG (2) SG182141A1 (enExample)
SI (1) SI2162467T1 (enExample)
TW (6) TW200907128A (enExample)
WO (3) WO2008149150A2 (enExample)
ZA (1) ZA200908470B (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
CN103254309B (zh) 2005-05-18 2017-09-26 埃博灵克斯股份有限公司 针对肿瘤坏死因子α的改进的纳米体TM
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
KR20100018040A (ko) 2007-06-06 2010-02-16 도만티스 리미티드 프로테아제 내성 폴리펩티드를 선택하는 방법
BRPI0812398A2 (pt) * 2007-06-06 2019-09-24 Domantis Ltd domínio variável simples de imunoglobulina anti-vegf, antagonista anti-vegf, domínio variável simples de imunoglobulina resistente à protease, uso do antagonista vegf, método para a dispensação oral ou dispensação de um medicamento ao trato gi de um paciente ou ao pulmão ou tecido pulmonar ou olho de um paciente, dispositivo de dispensação pulmonar, formulação oral, ligando específico duplo, ácido nucleico isolado ou recombinante, vetor, célula hospedeira, método para produzir polipeptídeo, composição farmacêutica, polipeptídeo, e, proteína de fusão
CA2707986A1 (en) * 2007-12-13 2009-06-18 Glaxo Group Limited Compositions for pulmonary delivery
WO2009127691A1 (en) 2008-04-17 2009-10-22 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
PT2307454T (pt) 2008-06-25 2017-04-26 Esbatech Alcon Biomed Res Unit Anticorpos estáveis e solúveis que inibem o vegf
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
CN102224169A (zh) * 2008-11-26 2011-10-19 葛兰素集团有限公司 多肽、抗体可变结构域和拮抗剂
WO2010081787A1 (en) 2009-01-14 2010-07-22 Domantis Limited IMPROVED TNFα ANTAGONISM, PROPHYLAXIS & THERAPY WITH REDUCED ORGAN NECROSIS
BRPI1008014A2 (pt) * 2009-02-19 2016-10-04 Glaxo Group Ltd domínio variável simples, ligante multiespecífico, antagonistas de tnfr1, e de receptor de tnf-alfa, uso do agonista de tnfr, antagonista anti-tnfr1, polipeptídeo ou ligante multiespecífico, método para tratar e/ou prevenir uma condição ou doença, ácido nucleico, vetor, e, hospedeiro
AU2010215482B2 (en) 2009-02-19 2014-02-13 Glaxo Group Limited Improved anti-serum albumin binding variants
EA027866B1 (ru) 2009-02-19 2017-09-29 Глэксо Груп Лимитед Улучшенные связывающие сывороточный альбумин варианты
EP2401298A1 (en) 2009-02-24 2012-01-04 Glaxo Group Limited Antigen-binding constructs
BR112012001681A2 (pt) 2009-07-16 2019-09-24 Graxo Group Ltd domínios variáveis de ligação de anti-albumina sérica aperfeiçoados
JP2012532619A (ja) * 2009-07-16 2012-12-20 グラクソ グループ リミテッド Ｔｎｆｒ１を部分的に阻害するためのアンタゴニスト、用途および方法
WO2011047215A1 (en) * 2009-10-14 2011-04-21 Aileron Therapeutics, Inc. Improved peptidomimetic macrocycles
EP2493504B1 (en) 2009-10-27 2015-10-07 Glaxo Group Limited Stable anti-tnfr1 polypeptides, antibody variable domains and antagonists
WO2011095545A1 (en) 2010-02-05 2011-08-11 Ablynx Nv Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
EA201291009A1 (ru) * 2010-05-20 2013-05-30 Глаксо Груп Лимитед Улучшенные связывающие варианты против сывороточного альбумина
US9012609B2 (en) * 2010-08-13 2015-04-21 Glaxosmithkline Intellectual Property Development Limited Anti-serum albumin binding variants
KR20130055663A (ko) 2010-08-20 2013-05-28 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 개선된 항-혈청 알부민 결합 변이체
CA2810465C (en) * 2010-09-16 2018-10-02 Baliopharm Ag Anti-hutnfr1 antibody
US20130266567A1 (en) 2010-12-01 2013-10-10 Haren Arulanantham Anti-serum albumin binding single variable domains
EP2670778A1 (en) * 2011-02-02 2013-12-11 Glaxo Group Limited Novel antigen binding proteins
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
UA124083C2 (uk) 2011-06-28 2021-07-21 ІНГІБРЕКС, Інк. Злитий серпіновий поліпептид і спосіб його застосування
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
MX2014001019A (es) * 2011-07-27 2014-05-13 Glaxo Group Ltd Dominios variables singulares anti-vgf fusionados con dominios de fc.
PE20141522A1 (es) * 2011-08-17 2014-11-17 Glaxo Group Ltd Proteinas y peptidos modificados
GB2497138A (en) * 2011-12-02 2013-06-05 Randox Lab Ltd Biomarkers for stroke and stroke subtype diagnosis.
SG11201408538PA (en) 2012-07-13 2015-02-27 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
WO2014111550A1 (en) 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
TW201514193A (zh) 2013-01-31 2015-04-16 Glaxo Group Ltd 製備蛋白質之方法
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
MA41374A (fr) * 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
WO2017117464A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
GB201617622D0 (en) * 2016-10-18 2016-11-30 VIB VZW and Universiteit Gent Means and methods to treat inflammation
RU2625010C1 (ru) * 2016-11-10 2017-07-11 Илья Петрович Приколаб Экспрессионный плазмидный вектор для экспрессии активной формы TNFR1-Fc и способ получения рекомбинантного белка
CA3039316A1 (en) 2016-11-28 2018-05-31 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule having adjustable ligand binding activity
CN110177875B (zh) 2016-11-28 2023-11-28 中外制药株式会社 包含抗原结合结构域和运送部分的多肽
UY37651A (es) * 2017-03-31 2018-10-31 Swedish Orphan Biovitrum Ab Publ Polipéptido de unión al il-1r-i
AU2018359532C9 (en) * 2017-11-01 2025-02-13 Allogene Therapeutics, Inc. Modified caspase-9 polypeptides and methods of use thereof
BR112020010450A2 (pt) 2017-11-28 2020-11-24 Chugai Seiyaku Kabushiki Kaisha polipeptídeo que inclui domínio de ligação a antígeno e seção transportadora
WO2019107384A1 (ja) 2017-11-28 2019-06-06 中外製薬株式会社 リガンド結合活性が調整可能なリガンド結合分子
BR112020017872A2 (pt) 2018-03-02 2020-12-22 Kodiak Sciences Inc. Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
US12077577B2 (en) 2018-05-30 2024-09-03 Chugai Seiyaku Kabushiki Kaisha Polypeptide comprising aggrecan binding domain and carrying moiety
EP3802831A4 (en) * 2018-05-30 2022-07-27 Chugai Seiyaku Kabushiki Kaisha Polypeptide comprising il-1r1 binding domain and carrying moiety
EP3623798B1 (de) * 2018-09-13 2021-11-03 Euroimmun Medizinische Labordiagnostika AG Verfahren und vorrichtung zum erfassen und darstellen eines immunfluoreszenzbildes einer biologischen probe
EP3870331B1 (en) * 2018-10-25 2025-07-23 F. Hoffmann-La Roche AG Modification of antibody fcrn binding
CA3120327A1 (en) 2018-12-06 2020-06-11 Cytomx Therapeutics, Inc. Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
CN111454366B (zh) * 2019-01-21 2023-06-16 中国科学院深圳先进技术研究院 一种融合蛋白及其应用
CN113728233B (zh) * 2019-01-31 2024-09-13 积水医疗株式会社 用于生物样品中的游离aim的免疫分析方法和分析试剂盒
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
JP7473398B2 (ja) * 2020-05-28 2024-04-23 シスメックス株式会社 キャリブレータ、複合体、及びＩｇＡ凝集体を測定する方法
JP2023541816A (ja) 2020-08-27 2023-10-04 イノージ・セラピューティクス・コーポレイション 自己免疫性疾患および癌を治療するための方法および組成物
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
CN115181751A (zh) * 2021-04-02 2022-10-14 苏州博腾生物制药有限公司 靶向白蛋白的嵌合抗原受体及其使用方法
CN114657162B (zh) * 2022-03-04 2023-06-16 华南理工大学 一种具有血管内皮细胞保护功能的抗氧化五肽及其应用
CN115112704B (zh) * 2022-06-21 2025-07-15 中特检验集团有限公司 一种光热发电有机热载体热稳定性检测方法
AR129879A1 (es) 2022-07-08 2024-10-09 Novo Nordisk As Compuestos de isvd altamente potentes capaces de sustituir al fviii(a)
WO2025049818A1 (en) 2023-08-29 2025-03-06 Enosi Therapeutics Corporation Tnfr1 antagonists lacking agonist activity and uses thereof
CN119909772B (zh) * 2025-04-01 2025-06-20 安徽一帆新材料科技有限公司 用于净水的再生阴树脂及其制备方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
WO1989007142A1 (en) 1988-02-05 1989-08-10 Morrison Sherie L Domain-modified constant region antibodies
EP1997891A1 (en) 1988-09-02 2008-12-03 Dyax Corporation Generation and selection of recombinant varied binding proteins
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
DE69132531T2 (de) 1990-12-06 2001-09-13 Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) Verbindungen und ihre Verwendung in einer binären Synthesestrategie
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US5702892A (en) 1995-05-09 1997-12-30 The United States Of America As Represented By The Department Of Health And Human Services Phage-display of immunoglobulin heavy chain libraries
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
DE69721548T2 (de) * 1996-02-09 2004-04-01 Abbott Laboratories(Bermuda)Ltd. HUMANE ANTIKÖRPER WELCHE AN HUMANEN TNFalpha BINDEN
DK1801214T3 (da) 1997-07-07 2011-01-24 Medical Res Council In vitro sorteringsfremgangsmåde
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
ATE380865T1 (de) 1998-05-13 2007-12-15 Domantis Ltd Phagen-display-selektionssystem für korrekt gefaltete proteine
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
AU2002219944B2 (en) 2000-11-28 2008-02-21 Medimmune, Llc Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
JP2003523742A (ja) 2000-02-03 2003-08-12 ドマンティス リミテッド コンビナトリアルタンパク質ドメイン
WO2001058953A2 (en) 2000-02-11 2001-08-16 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
US7265210B2 (en) * 2000-09-15 2007-09-04 Genentech, Inc. Anti-PRO9821 antibodies
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
DE60237282D1 (de) 2001-06-28 2010-09-23 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
GB0118689D0 (en) * 2001-08-01 2001-09-19 Psimedica Ltd Pharmaceutical formulation
WO2003076567A2 (en) 2002-03-05 2003-09-18 Eli Lilly And Company Heterologous g-csf fusion proteins
DK1517921T3 (da) 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US20060002935A1 (en) * 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
PL377091A1 (pl) 2002-09-06 2006-01-23 Amgen, Inc. Ludzkie monoklonalne przeciwciało przeciw-IL-1R1, o właściwościach terapeutycznych
EP1545611B1 (en) 2002-09-06 2016-11-09 Alexion Pharmaceuticals, Inc. Method of treatment of asthma using antibodies to complement component c5
EP3299393A1 (en) 2002-11-08 2018-03-28 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
CA2511910A1 (en) 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
GB0230203D0 (en) * 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
US20060104968A1 (en) * 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
DK1639011T3 (da) * 2003-06-30 2009-02-16 Domantis Ltd Pegylerede enkelt-domæne antistoffer (dAb)
SI1729795T1 (sl) 2004-02-09 2016-04-29 Human Genome Sciences, Inc. Albuminski fuzijski proteini
PT1737962E (pt) 2004-03-24 2010-12-03 Domantis Ltd Sequência líder universal gas1
EP2311433A3 (en) * 2004-10-21 2011-08-10 Genentech, Inc. Method for treating intraocular neovascular diseases
GB0521621D0 (en) * 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
KR20070086896A (ko) * 2004-12-02 2007-08-27 도만티스 리미티드 항­ｉｌ­1ｒ1 단일 도메인 항체 및 치료적 용도
EP1957537A2 (en) 2005-12-01 2008-08-20 Domantis Limited Competitive domain antibody formats that bind interleukin 1 receptor type 1
KR20080077238A (ko) 2005-12-01 2008-08-21 도만티스 리미티드 인터루킨 1 수용체 타입 1에 결합하는 비경쟁적 도메인항체 포맷
CA2660519A1 (en) 2006-08-10 2008-02-21 Roy C. Levitt Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors
EP2081960B1 (en) * 2006-10-27 2018-06-27 Ablynx N.V. Intranasal delivery of polypeptides and proteins
BRPI0812398A2 (pt) 2007-06-06 2019-09-24 Domantis Ltd domínio variável simples de imunoglobulina anti-vegf, antagonista anti-vegf, domínio variável simples de imunoglobulina resistente à protease, uso do antagonista vegf, método para a dispensação oral ou dispensação de um medicamento ao trato gi de um paciente ou ao pulmão ou tecido pulmonar ou olho de um paciente, dispositivo de dispensação pulmonar, formulação oral, ligando específico duplo, ácido nucleico isolado ou recombinante, vetor, célula hospedeira, método para produzir polipeptídeo, composição farmacêutica, polipeptídeo, e, proteína de fusão
KR20100018040A (ko) 2007-06-06 2010-02-16 도만티스 리미티드 프로테아제 내성 폴리펩티드를 선택하는 방법

Also Published As

Publication number Publication date
WO2008149150A2 (en) 2008-12-11
MX2009013138A (es) 2010-04-30
EP2162468A2 (en) 2010-03-17
EP2746290B1 (en) 2019-08-14
BRPI0812795A2 (pt) 2014-12-02
CR11195A (es) 2010-05-24
TW200911832A (en) 2009-03-16
BRPI0812268A2 (pt) 2019-09-10
EP2746291B1 (en) 2019-08-14
CY1116762T1 (el) 2017-03-15
EA200901494A1 (ru) 2010-06-30
CL2008001674A1 (es) 2008-11-21
CO6251321A2 (es) 2011-02-21
MX2009012967A (es) 2010-04-01
DOP2009000268A (es) 2010-02-28
NZ581372A (en) 2012-02-24
AU2008259590A1 (en) 2008-12-11
AU2008259514A1 (en) 2008-12-11
KR20100021642A (ko) 2010-02-25
AU2008259514B2 (en) 2014-05-15
AR066847A1 (es) 2009-09-16
BRPI0813899A2 (pt) 2019-09-24
AR066848A1 (es) 2009-09-16
JP2010529841A (ja) 2010-09-02
PL2162467T3 (pl) 2015-12-31
TW200902551A (en) 2009-01-16
BRPI0812795B1 (pt) 2019-12-03
EA018723B1 (ru) 2013-10-30
TW200911834A (en) 2009-03-16
KR20100041746A (ko) 2010-04-22
CA2683823A1 (en) 2008-12-11
HRP20151024T1 (hr) 2015-11-06
DK2162467T3 (en) 2015-08-24
HK1138022A1 (en) 2010-08-13
KR20100018040A (ko) 2010-02-16
CA2688447A1 (en) 2008-12-11
TW200911831A (en) 2009-03-16
US20090148437A1 (en) 2009-06-11
SG182141A1 (en) 2012-07-30
US20120134982A1 (en) 2012-05-31
EP2162467B1 (en) 2015-07-22
PE20090763A1 (es) 2009-07-10
BRPI0812795B8 (pt) 2020-01-28
US20100266616A1 (en) 2010-10-21
CN101778865A (zh) 2010-07-14
CN104311663A (zh) 2015-01-28
HUE025899T2 (en) 2016-05-30
CA2688433A1 (en) 2008-12-11
CA2683791A1 (en) 2008-12-11
CA2688434A1 (en) 2008-12-11
EP2162467A2 (en) 2010-03-17
WO2008149149A2 (en) 2008-12-11
EA200901300A1 (ru) 2010-06-30
CN101778865B (zh) 2016-11-09
SI2162467T1 (sl) 2015-11-30
CO6251322A2 (es) 2011-02-21
KR101604274B1 (ko) 2016-03-17
JP5325211B2 (ja) 2013-10-23
CR11194A (es) 2010-06-28
IL202204A0 (en) 2010-06-16
PE20090323A1 (es) 2009-04-20
EP2746291A3 (en) 2014-09-03
SG182151A1 (en) 2012-07-30
EA200901491A1 (ru) 2010-08-30
JP2010530364A (ja) 2010-09-09
US20110256122A1 (en) 2011-10-20
EP2746291A2 (en) 2014-06-25
CN104311663B (zh) 2018-11-02
MA31668B1 (fr) 2010-09-01
EA018129B1 (ru) 2013-05-30
TW200918088A (en) 2009-05-01
US8398979B2 (en) 2013-03-19
WO2008149148A3 (en) 2009-04-02
PT2162467E (pt) 2015-10-29
WO2008149148A2 (en) 2008-12-11
EP2164867A2 (en) 2010-03-24
EA200901495A1 (ru) 2010-10-29
MA31403B1 (fr) 2010-05-03
ES2546943T3 (es) 2015-09-30
CN101802004A (zh) 2010-08-11
JP2010530220A (ja) 2010-09-09
MX2009013137A (es) 2010-04-30
AR066850A1 (es) 2009-09-16
PE20090322A1 (es) 2009-04-20
CA2688456A1 (en) 2008-12-11
TW200907128A (en) 2009-02-16
KR20100040841A (ko) 2010-04-21
WO2008149150A3 (en) 2009-06-25
JP5444215B2 (ja) 2014-03-19
CA2688447C (en) 2016-11-08
EP2746290A2 (en) 2014-06-25
WO2008149149A3 (en) 2009-04-02
MX2009013211A (es) 2010-04-09
CN101883788A (zh) 2010-11-10
ZA200908470B (en) 2011-02-23
CL2008001673A1 (es) 2008-11-21
AU2008259515A1 (en) 2008-12-11
US20100247515A1 (en) 2010-09-30
IL201398A0 (en) 2010-05-31
EP2746290A3 (en) 2014-09-10
CL2008001676A1 (es) 2008-11-21
EA201100546A1 (ru) 2011-12-30
AU2008259516A1 (en) 2008-12-11

Similar Documents

Publication Publication Date Title
BRPI0812795C1 (pt) domínio variável único de imunoglobulina, antagonista tipo 1 do receptor tnfalfa, uso de um domínio ou antagonista de tnfr1, ácido nucleico recombinante, vetor, célula hospedeira, e, composição farmacêutica
BRPI0812398A2 (pt) domínio variável simples de imunoglobulina anti-vegf, antagonista anti-vegf, domínio variável simples de imunoglobulina resistente à protease, uso do antagonista vegf, método para a dispensação oral ou dispensação de um medicamento ao trato gi de um paciente ou ao pulmão ou tecido pulmonar ou olho de um paciente, dispositivo de dispensação pulmonar, formulação oral, ligando específico duplo, ácido nucleico isolado ou recombinante, vetor, célula hospedeira, método para produzir polipeptídeo, composição farmacêutica, polipeptídeo, e, proteína de fusão
WO2008149146A3 (en) Polypeptides, antibody variable domains and antagonists
CY1116952T1 (el) Ειδικες και υψηλης συγγενειας δεσμευομενες πρωτεϊνες που περιλαμβανουν τροποποιημενες περιοχες sh3 κινασης fyn
BR112013029409A8 (pt) produtos farmacêuticos de peptídeo melhorados para resistência à insulina
BRPI0819932A2 (pt) composição, uso de uma composição, dispositivo nebulizador, inalador ou intranasal, processos para produzir uma composição farmacêutica e uma composição polipeptídica, e, uso de um tampão fisiologicamente aceitável.
PL397167A1 (pl) Przeciwnowotworowe bialko fuzyjne
BR112016008125B1 (pt) Domínio proteico isolado de fibronectina tipo iii modificado com cisteína, seu método de produção e método para produzir uma molécula isolada de de fibronectina tipo iii biespecífica modificada com cisteína
JP2016527286A5 (enExample)
BRPI0619225A2 (pt) monômero de anticorpo de domínio, ligando, ácidos nucleicos isolado e recombinante, vetor, célula hospedeira, método para produzir um monômero de dab de ligando, composição farmacêutica, dispositivo de liberação de medicamento, uso de um monômero de anticorpo de domínio, e, método para tratar uma doença inflamatória, artrite ou doença respiratória
BRPI0619224A2 (pt) monômero de anticorpo de domínio, ligando, ácidos nucleicos isolado e recombinante, vetor, célula hospedeira, método para produzir um monômero de dab de ligando, composição farmacêutica, dispositivo de liberação de medicamento, uso de um monômero de anticorpo de domínio, e, método para tratar uma doença inflamatória, artrite ou doença respiratória
EA201001357A1 (ru) Слитые конструкции и конъюгаты лекарственного средства
BR112012007374A2 (pt) composição, formulação oral, injetável, inalável ou nebulizável, e, ácido nucleico isolado ou recombinante
HRP20150664T1 (hr) Antikancerogeni fuzijski protein
JP2016524592A5 (enExample)
BRPI0513798A (pt) anticorpos anti-cd154
US20160060307A1 (en) Human ferritin-derived fusion polypeptide
WO2010094720A3 (en) Improved anti-tnfr1 polypeptides, antibody variable domains & antagonists
ES2883933T3 (es) Métodos de uso mejorados para secretoglobinas humanas recombinantes
BR112018073669A2 (pt) proteína de fusão, composição de uma primeira proteína e uma segunda proteína, complexo de uma primeira proteína e uma segunda proteína, polinucleotídeos que codificam uma proteína de fusão, vetor contendo o polinucleotídeo, célula hospedeira contendo o polinucleotídeo, uso de uma proteína de fusão, composição farmacêutica, e composição farmacêutica para uso
EP3955956A1 (en) Therapeutic crosslinking of cytokine receptors
ES2908078T3 (es) Usos médicos que implican mutantes C-RAF que confieren resistencia a los inhibidores de RAF
ES2731257T3 (es) Moléculas de unión al receptor de BAG3 para su uso como un medicamento
ES2804907T3 (es) Biblioteca de polipéptidos
JP2018510213A5 (enExample)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/12/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/12/2019, OBSERVADAS AS CONDICOES LEGAIS

B09W Correction of the decision to grant [chapter 9.1.4 patent gazette]

Free format text: RETIFICA A PUBLICACAO 9.1 DA RPI NO 2548 (05/11/2019) POR TER SIDO EFETUADA COM INCORRECOES.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI 2552 DE 03/12/2019, QUANTO AO RELATORIO DESCRITIVO.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/06/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2726 DE 04-04-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.